Drug-eluting stents - Emerging trends

A few years after their introduction in 2002, drug-eluting stents had all but replaced bare-metal stents in the treatment of coronary heart disease, capturing up to 90% of the market. PMost of the pysicians favored the new stents primarily because of their ability to minimize the risk of restenosis associated with bare-metal stents.

Recently, however, new safety concerns have begun to erode the market share of drug-eluting stents.

Comments

Popular posts from this blog

Databases on the FDA Website

IPEXL - New Patent Search Tool

Employee Retention – A critical issue, why..and How to solve?